Hayashi K
Department of Legal Medicine, Graduate School of Medicine, Kyorin University, Shinkawa 6-20-2, Mitaka-City, Tokyo 181-8611, Japan.
Nihon Arukoru Yakubutsu Igakkai Zasshi. 2000 Oct;35(5):306-20.
The fibrates are widely used for the reduction of high triglyceride levels. The fibrates act as the peroxisome proliferator-activated receptor alpha ligands to regulate the transcription of large number of genes that affect lipoprotein and fatty acid metabolism. The male rats of Wistar strain, simfibrate-treated (100 mg/kg, 200 mg/kg) or clinofibrate-treated (50 mg/kg, 100 mg/kg), were given ethanol (2 g/kg) orally. Blood ethanol levels on the simfibrate groups (100 mg/kg, 200 mg/kg) were significantly lower than the control groups (p < 0.01). The clinofibrate groups (100 mg/kg) were also lower than the controls (p < 0.05). The fatty acid beta-oxidation activity of liver peroxisome in simfibrate-treated (200 mg/kg) or clinofibrate-treated (100 mg/kg) rats for single administration (2.5 hours before the measurement) and twice administrations (20 and 1 hours before the measurement) were assayed. The activity ratio was 168% in simfibrate (p < 0.05), 146% in clinofibrate in single administration, and 388% in simfibrate (p < 0.01), 200% in clinofibrate (p < 0.01) in twice administrations. Alcohol dehydrogenase of cytosol and aldehyde dehydrogenase of cytosol, microsome and mitochondria in the liver were not induced by these fibrates. These results were suggested that simfibrate and clinofibrate induced beta-oxidation by peroxisome and increased H2O2 production, which led to augmented ethanol metabolism by catalase.
贝特类药物被广泛用于降低高甘油三酯水平。贝特类药物作为过氧化物酶体增殖物激活受体α配体,可调节大量影响脂蛋白和脂肪酸代谢的基因转录。给Wistar品系的雄性大鼠口服乙醇(2 g/kg),这些大鼠分别接受辛伐贝特(100 mg/kg、200 mg/kg)或氯贝丁酯(50 mg/kg、100 mg/kg)治疗。辛伐贝特组(100 mg/kg、200 mg/kg)的血液乙醇水平显著低于对照组(p < 0.01)。氯贝丁酯组(100 mg/kg)也低于对照组(p < 0.05)。对单次给药(测量前2.5小时)和两次给药(测量前20小时和1小时)的辛伐贝特(200 mg/kg)或氯贝丁酯(100 mg/kg)治疗的大鼠肝脏过氧化物酶体的脂肪酸β氧化活性进行了测定。单次给药时,辛伐贝特的活性比率为168%(p < 0.05),氯贝丁酯为146%;两次给药时,辛伐贝特为388%(p < 0.01),氯贝丁酯为200%(p < 0.01)。这些贝特类药物未诱导肝脏胞质溶胶中的乙醇脱氢酶以及胞质溶胶、微粒体和线粒体中的乙醛脱氢酶。这些结果表明,辛伐贝特和氯贝丁酯通过过氧化物酶体诱导β氧化并增加过氧化氢的产生,从而导致过氧化氢酶增强乙醇代谢。